Associate Professor, Department of Hematology/Oncology
Vice Chair, Clinical Research, Department of Hematology/Oncology
Chief, Section of Solid Tumor Oncology
Co-Director, Melanoma and Skin Cancer Program
Director, Early Clinical Drug Development Phase 1 Program
National Comprehensive Cancer Network (NCCN)
Thymoma, Esophageal Cancer, Lung Metastases, Neuroendocrine Tumors, Stomach (Gastric) Cancer, Endobronchial Disease, Lung Cancer, Mesothelioma, Skin Cancer, Colorectal Cancer, Liver, Gall Bladder & Bile Duct Cancer, Melanoma, Pancreatic Cancer
Early Clinical Drug Development/Phase 1 Trials; Melanoma and skin cancer; Lung cancers; Gastrointestinal cancers
I believe that the path towards treating any disease is best navigated by thoroughly understanding not only the disease, but also the patient. Good communication between a physician and a patient is especially critical in the treatment of cancer. Each patient has a right to be both respected and heard. In addition, relying on a team of experts to help manage the complexities of treating cancer is essential for success. As a physician, I strive to provide personalized and scientifically sound care to each of my patients.
My medical career started out as a pharmacist, specializing in oncology, where I prepared chemotherapy regimens and studied the effects the body has on drugs (pharmacokinetics). When I went to medical school, it was for the sole purpose of eventually becoming an oncologist. During my hematology/oncology and clinical pharmacology fellowships, I spent a great deal of time in early clinical development, with a goal of finding new effective therapies for patients with cancer. I honed my knowledge of drug discovery by spending five years in the pharmaceutical industry where I led multiple programs aimed at treating patients with cancers that didn’t respond to traditional chemotherapy. Today, my interests focus on early drug development for all types of cancers, and understanding how each medication may best be used. In addition I specifically focus on the treatment of lung cancer, skin cancers including melanoma, and gastrointestinal malignancies.
In many situations, the best medical care a patient with cancer can get is on a clinical trial. These clinical trials offer patients potentially promising new therapies and very close follow up supplied by a team of experts. Fox Chase Cancer Center, with its leading-edge technology and dedicated medical professionals, offers numerous clinical trials and is helping to advance the care of all patients with cancer.
The staff at Fox Chase Cancer Center continually impress me with their unified commitment towards reducing the burden of cancer. When you step through the doors at Fox Chase Cancer Center, it is obvious that focusing on the patient is the top priority. I am proud to be a member of the caring community at FCCC, where oncology research and science is tailored and personalized for each patient.
I plan on having a very, very long life. I’m 66 years old and I run a daycare in Havertown, Pennsylvania. Until I was diagnosed, I had no symptoms to speak of and had lived a healthy lifestyle. That’s why when doctors told me I had carcinoid tumors, I had trouble believing I was really sick.
I’m an active guy. I like to fish, play golf, travel, dance, and go off-roading. When something goes wrong, rather than sitting around feeling bad, I do anything in my power to remedy the situation. In 2013, this philosophy was severely tested when I was diagnosed with a rare cancer.
The level of teamwork and communication amongst the doctors was reassuring. Even though I felt overwhelmed by multiple surgeries, treatments, and diagnoses, I took immense comfort in the prompt actions taken my team of physicians.
Hong D.S., Rixe O., Chiu V.K., Forde P.M., Dragovich T., Lou Y., Nayak-Kapoor A., Leidner R., Atkins J.N., Collaku A., Fox F.E., Marshall M.A., Olszanski A.J., Mogamulizumab in combination with nivolumab in a phase i/ii study of patients with locally advanced or metastatic solid tumors. Clin Cancer Res. 28(3): 479-488, 2022. https://www.ncbi.nlm.nih.gov/pubmed/34753777.
Marinova A.M., Reilly J.L., Wong V., Weiss S., Olszanski A.J., Metastatic melanoma with leptomeningeal disease. J Adv Pract Oncol. 12(1): 79-83, 2021.PMC7844196. https://www.ncbi.nlm.nih.gov/pubmed/33552663.
Hong DS, Rixe O, Chiu VK, Forde PM, Dragovich T, Lou Y, Nayak-Kapoor A, Leidner R, Atkins JN, Collaku A, Fox FE, Marshall MA, Olszanski AJ. Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors. Clin Cancer Res. 2021 Nov 9;. doi: 10.1158/1078-0432.CCR-21-2781. [Epub ahead of print] PubMed
Wagner J, Kline CL, Zhou LL, Campbell KS, MacFarlane AW, Olszanski AJ, Cai KQ, Hensley HH, Ross EA, Ralff MD, Zloza A, Chesson CB, Newman JH, Kaufman H, Bertino J, Stein M, El-Deiry WS. Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment. Journal of Clinical Investigation, 128(6):2325-38, 2018. PubMed
Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors. Zibelman M, Wong YN, Devarajan K, Malizzia L, Corrigan A, et al. Investigational new drugs. 2015; 33(5):1040-7. PubMed
Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies. Rixe O, Puzanov I, LoRusso PM, Cohen RB, Morris JC, et al. Anti-cancer drugs. 2015; 26(7):785-92. PubMed
Principles of immunotherapy. Olszanski AJ. Journal of the National Comprehensive Cancer Network : JNCCN. 2015; 13(5 Suppl):670-2. PubMed
Patient comments